KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash & Equivalents (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Cash & Equivalents data on record, last reported at $158.5 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 42.72% year-over-year to $158.5 million; the TTM value through Dec 2025 reached $158.5 million, down 42.72%, while the annual FY2025 figure was $158.5 million, 42.72% down from the prior year.
  • Cash & Equivalents reached $158.5 million in Q4 2025 per PCRX's latest filing, up from $147.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $585.6 million in Q4 2021 and bottomed at $35.5 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $183.7 million, with a median of $150.4 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 485.83% in 2021, then crashed 84.32% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $585.6 million in 2021, then crashed by 82.22% to $104.1 million in 2022, then soared by 47.21% to $153.3 million in 2023, then skyrocketed by 80.55% to $276.8 million in 2024, then tumbled by 42.72% to $158.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $158.5 million in Q4 2025, $147.6 million in Q3 2025, and $300.5 million in Q2 2025.